COVID-19 和非 COVID-19 导致的急性呼吸窘迫综合征患者对低剂量类固醇的反应明显不同——一项回顾性观察研究。
COVID-19 and non-COVID ARDS patients demonstrate a distinct response to low dose steroids- A retrospective observational study.
机构信息
Bloomsbury Institute of Intensive Care Medicine, University College London, UK.
Bloomsbury Institute of Intensive Care Medicine, University College London, UK.
出版信息
J Crit Care. 2021 Apr;62:46-48. doi: 10.1016/j.jcrc.2020.11.012. Epub 2020 Nov 21.
Patients with COVID-19 ARDS have distinct physiological and immunological phenotypes compared to patients with non-COVID ARDS. Patients with COVID-19 ARDS (n = 32) had a significant improvement in PaO: FiO ratio (p = 0.046) following low-dose steroid treatment, unlike patients with non-COVID ARDS (n = 16) (p = 0.529). Patients with COVID-19 ARDS had a greater fall in CRP compared to patients with non-COVID ARDS, albeit not statistically significant (p = 0.07). Our novel findings highlight differences in the underlying physiological and immunological phenotypes between COVID-19 and non-COVID ARDS, with implications for future ARDS studies.
与非 COVID-19 ARDS 患者相比，COVID-19 ARDS 患者具有明显不同的生理和免疫表型。与非 COVID-19 ARDS 患者（n=16）相比，接受低剂量类固醇治疗后 COVID-19 ARDS 患者（n=32）的 PaO:FiO 比值有显著改善（p=0.046）（p=0.529）。尽管 COVID-19 ARDS 患者 CRP 下降幅度大于非 COVID-19 ARDS 患者，但无统计学意义（p=0.07）。我们的新发现强调了 COVID-19 和非 COVID-19 ARDS 之间潜在生理和免疫表型的差异，这对未来的 ARDS 研究具有重要意义。
Zotero 插件